An analysis of the epitope knowledge related to Mycobacteria by Blythe, Martin J et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
Immunome Research
Open Access Research
An analysis of the epitope knowledge related to Mycobacteria
Martin J Blythe*1, Qing Zhang1, Kerrie Vaughan1, Romulo de Castro Jr1, 
Nima Salimi1, Huynh-Hoa Bui1, David M Lewinsohn2, Joel D Ernst3, 
Bjoern Peters1 and Alessandro Sette1
Address: 1Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, California, 92037, USA, 
2Portland VA Medical Center/Oregon Heath and Science University, R&D 11, PVAMC, 3710 SW US Veterans Road, Portland, Oregon, 97239, USA 
and 3Division of Infectious Diseases, New York University School of Medicine, 550 First Avenue, Smilow 901, New York, 10016, USA
Email: Martin J Blythe* - mblythe@liai.org; Qing Zhang - qlehmann@liai.org; Kerrie Vaughan - kvaughan@liai.org; Romulo de 
Castro - jongdc@liai.org; Nima Salimi - nsalimi@liai.org; Huynh-Hoa Bui - hbui@liai.org; David M Lewinsohn - lewinsod@ohsu.edu; 
Joel D Ernst - joel.ernst@med.nyu.edu; Bjoern Peters - bpeters@liai.org; Alessandro Sette - alex@liai.org
* Corresponding author    
Abstract
Background: Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, remains a leading cause
of infectious disease morbidity and mortality, and is responsible for more than 2 million deaths a year.
Reports about extremely drug resistant (XDR) strains have further heightened the sense of urgency for
the development of novel strategies to prevent and treat TB. Detailed knowledge of the epitopes
recognized by immune responses can aid in vaccine and diagnostics development, and provides important
tools for basic research. The analysis of epitope data corresponding to M. tuberculosis can also identify gaps
in our knowledge, and suggest potential areas for further research and discovery. The Immune Epitope
Database (IEDB) is compiled mainly from literature sources, and describes a broad array of source
organisms, including M. tuberculosis and other Mycobacterial species.
Description: A comprehensive analysis of IEDB data regarding the genus Mycobacteria was performed.
The distribution of antibody/B cell and T cell epitopes was analyzed in terms of their associated recognition
cell type effector function and chemical properties. The various species, strains and proteins which the
epitope were derived, were also examined. Additional variables considered were the host in which the
epitopes were defined, the specific TB disease state associated with epitope recognition, and the HLA
associated with disease susceptibility and endemic regions were also scrutinized. Finally, based on these
results, standardized reference datasets of mycobacterial epitopes were generated.
Conclusion: All current TB-related epitope data was cataloged for the first time from the published
literature. The resulting inventory of more than a thousand different epitopes should prove a useful tool
for the broad scientific community. Knowledge gaps specific to TB epitope data were also identified. In
summary, few non-peptidic or post-translationally modified epitopes have been defined. Most importantly
epitopes have apparently been defined from only 7% of all ORFs, and the top 30 most frequently studied
protein antigens contain 65% of the epitopes, leaving the majority of M. tuberculosis genome unexplored.
A lack of information related to the specific strains from which epitopes are derived is also evident. Finally,
the generation of reference lists of mycobacterial epitopes should also facilitate future vaccine and
diagnostic research.
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Background
The goal of the Immune Epitope Database and Analysis
Resource (IEDB) [1] is to compile epitope-specific immu-
nological data, as well as analysis tools, and to facilitate
the characterization of immune responses in humans and
other higher vertebrates. Epitope information can be use-
ful to the scientific community in the design, characteriza-
tion, and identification of potential vaccines and
diagnostics, as well as to assist in basic investigation of
immune responses and host-pathogen interactions. In
terms of the type of immune responses and associated
epitopes considered, we describe epitopes recognized in
the context of the adaptive immune response, namely
antibody/B and T cell epitopes. Each type of epitope is
defined as the molecular structure that is bound by an
antibody or T cell receptor.
Curation of data relating to NIAID Category A, B, and C
pathogens [2], emerging and re-emerging infectious dis-
eases and various other pathogens into the IEDB is current
with the published literature (see [1] for a current list). To
date, the database describes epitopes sourced from over
4,000 publications detailing in excess of 32,000 distinct
epitopes. Besides epitopes composed of amino acids, the
IEDB includes information from all other chemical classes
of non-peptidic antigens, including lipids, glycolipids,
carbohydrates, DNA, RNA, and small organic molecules.
The information can be searched using multiple parame-
ters. For each epitope, specific fields summarize immuno-
logical data, including detailed information related to the
immunized/infected host organism and source of the
antigenic determinant. Associated fields also describe the
experimental techniques used to characterize the epitope,
and the immunological response detected [3,4]. The IEDB
also hosts various bioinformaticstools to analyze epitope
data, including: populationcoverage [5]; epitope conserv-
ancy and prediction of cellular processing [6]; binding to
MHC molecules [7-9];homology mapping of linear anti-
body epitopes; and 3D structure rendering [10]. The IEDB
represents a useful platform upon which comprehensive
analyses can be performed for a given host or pathogen of
interest.
The mycobacterium M. tuberculosis (Mtb) is a highly trans-
mittable human pathogen that causes tuberculosis (TB)
and is responsible for more than 2 million deaths globally
each year [11]. The uncertain efficacy of the Bacillus Cal-
mette-Guerin (BCG) vaccine for TB in adults, and the
emergence of extensively drug resistant Mtb strains have
further enhanced the sense of urgency in the development
and characterization of TB vaccines and diagnostic rea-
gents [12]. Data specific to the immunology and patho-
genesis of TB are helpful in addressing these concerns by
facilitating the development and evaluation of new vac-
cines, therapeutics, and diagnostics, and fostering studies
to investigate host-pathogen interactions. Several compre-
hensive databases provide access to a variety of TB-related
information and research sources. These resources include
the BioHealthBase Bioinformatics Resource Center [13],
The Pasteur Institute TubercuList [14], The Institute for
Genomic Research (TIGR) Comprehensive Microbial
Resource (CMR) [15], Proteome Database System for
Microbial Research at the Max Planck Institute for Infec-
tion Biology [16], and the TB Vaccine Testing and
Research Materials Contract [16]. However, these data-
bases do not specifically capture/contain immunological
data related to TB and associated diseases. The detailed
context-dependent data captured within the IEDB there-
fore provides a unique resource.
Ample data demonstrate the relevance of B and T cell
epitopes in reposnse to mycobacterial infections, and for
diagnostic and vaccine applications [17-23]. Using the
epitope-specific immunological data within the IEDB, a
comprehensive analysis wasundertaken to compile and
characterize our current knowledge regarding adaptive
immunity to the genus Mycobacteria. This analysis was
conducted with the following aims: i) inventory our cur-
rent knowledge in the area of mycobacterium-related
immunological and epitope data to enhance clinical
research and to facilitate the development of vaccines and
diagnostic tools; ii) identify knowledge gaps from the cur-
rent literature; iii) help identify possible areas for future
Mtb-specific research; and iv) explore the generation of an
reference list of immune epitopes that characterize Mtb,
based on input from members of the wider TB scientific
community.
Results and Discussion
Different types of Mycobacterium epitopes described 
within the IEDB
Mycobacterial epitopes are described first in terms of their
recognition by the humoral and cellular immune
response. From a dataset of 1377 unique mycobacterial
epitopes (described in the methods section), 1114 are rec-
ognized by T cell responses, and 357 by B cell responses.
It should be noted that the sum total of the epitopes in the
B and T cell categories exceeds the total number of
epitopes, as some epitopes are recognized by both cell
types. The overall epitope distribution likely reflects the
dominance placed on the T cell response in investigating
mycobacterial infections, and/or experimental bias.
All but 34 epitopes are peptidic in nature. Of the non-pep-
tidic epitopes, 20 are recognized by B cells and 14 by T
cells. Of the B cell epitopes 15 are carbohydrates, 3 are
fatty acids, one is a glycolipid, and one is a small organic
molecule. Of the non-peptidic T cell epitopes 7 are small
organic molecules, and 4 are glycolipids, 2 are carbohy-
drates, and the last is a lipopeptide. These T cell epitopesImmunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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are restricted by class Ib/Non-classical MHC molecules.
The role of non-peptidic, post translationally-modified,
and capsular antigens in Mtb infectivity and pathogenesis,
as well as their potential diagnostic use, is well appreci-
ated [24,25]. Thus, this finding identifies a knowledge gap
in current epitope data, and highlights the need for the
generation of additional data defining non-peptidic and
post-translationally modified structures recognized by
host immunity against Mtb.
For this analysis, the assignment of effector cells as CD4+
versus CD8+ T cells was inferred from the assay type clas-
sification (described in the methods section) and there-
fore enabled a larger proportion of epitopes with no
reported restriction to be functionally/phenotypically cat-
egorized (Figure 1). This categorization showed that the
vast majority of epitopes have been defined for CD4+ T
cells, and have been described to a much lesser extent for
CD8+ T cells. Only a small number of effectors were cate-
gorized as non-classical (e.g. recognized by gamma-delta
T cells). The dominance of CD4+ epitopes likely represents
the focus of the research community in identifying
epitopes and antigens restricted by the MHC class II path-
way. A significant proportion of the T cell epitopes, mostly
described in references utilizing IFNγ and IL-2 assays,
remained unclassified due to lack of sufficient informa-
tion in the original publication regarding MHC restriction
and T cell phenotype. By contrast, the classification of B
cell epitopes as either linear/continuous or discontinuous
was clear-cut No discontinuous epitopes for Mycobacteria
have been found. This observation likely reflects the tech-
nological difficulties inherent in the definition of discon-
tinuous epitopes, but also highlights a crucial gap in our
knowledge of what is recognized during Mtb-specific
immune responses.
Topology and function of the protein sources from which 
the Mtb epitopes are derived
If we focus specifically on TB, we find that the M. tubercu-
losis genome comprises approximately 4000 protein cod-
ing ORFs, for which 924 epitopes are defined in the IEDB
from the literature. Most strikingly, these epitopes are
derived from only 270 ORFs, corresponding to a mere 7%
of the entire genome. In total, as few as 30 ORFs account
for 65% of the defined epitopes. Thus, epitope definition
studies in Mtb specifically, and mycobacterial species in
general, are apparently far from complete. We further ana-
lyzed the epitope distribution in the context of the func-
tion and topology of the protein of origin.
In order to explore the distribution of epitopes between
proteins according to function and topology category cat-
egories (described in the methods section), Epitope Den-
sity Index (EDI) values were determined. Two EDI values
were calculated for each category. The EDI 1 values repre-
sent the number of epitopes in each category divided by
the number of proteins (ORFs) with defined epitopes in
the category. The EDI 2 values represent the number of
epitopes in each category per 100 amino acid residues
from the same proteins, allowing protein size to be taken
into consideration (Figure 2). In general, epitopes within
the IEDB were identified from all functional and topolog-
ical categories that have defined coding sequences. A
small number of epitopes could not be classified, as their
source antigen sequences were either not known or not
homologous to the species of M. tuberculosis, M. bovis, M.
leprae, or M. avium.
In terms of protein function, the highest EDI 1 values
(8.84 to 5.90) were observed for proteins directly associ-
ated with pathogenicity (i.e. virulence, detoxification,
adaptation), lipid metabolism, followed by protein
classes that are probably exposed on the pathogen surface
(i.e. PE/PPE, cell wall and cell processes) (Figure 2a).
Fewer epitopes were derived from the organism's inter-
nally regulated proteins (i.e. information pathways, inter-
mediary metabolism and respiration, and regulatory
proteins), which had an EDI 1 range from 3.90 to 0.54. In
general, the EDI values calculated as a function of protein
length (EDI 2) correlate with EDI 1 values accept for PE/
PEE proteins, which were found to be larger on average.
These findings may represent an artifact of the early work
directed towards the secreted proteins of Mycobacteria
[26-28], while it is also consistent with current knowledge
for Mtb pathogenesis; an arsenal of secreted virulence fac-
The nature of antibody/B cell & T cell Mycobacterial epitopes Figure 1
The nature of antibody/B cell & T cell Mycobacterial 
epitopes. The proportion of mycobacterial epitopes accord-
ing to their type is shown. Where the type of T cell epitope 
could not be defined directly from the primary information 
source it was inferred from the assay type classification 
(described in the methods section).Immunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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tors and massive lipid metabolism work in concert to
establish infection [29,30].
Evidence of mycobacterial proteins changing subcellular
location [31], may have an impact on the overall topo-
graphical classification of epitopes, and indicates the need
to take experimental parameters into greater considera-
tion. With this caveat in mind, the highest EDI 1 values for
topology categories are seen in the extracelluar (11.49)
and cytoplasmic (8.09) proteins (Figure 2b). Their loca-
tions cohobate the findings of the protein function cate-
gories. The EDI 1 value for proteins with an undetermined
topology was less (5.18), while the lowest values were
seen for the cell wall (3.50) and cytoplasmic membrane
protein (3.06) categories. The correlation between EDI 1
and EDI 2 values differed for only the cytoplasmic protein
category, which have a smaller average size compared to
those with an undetermined topology. Finally, the ratio of
antibody/B cell and T cell epitopes was equivalent in each
protein function and topology category (data not shown).
It is important to note that the above analysis must be
viewed with the consideration of biological phenomenon
versus experimental bias. It is possible that protein classes
described above are highly immunogenic and could rep-
resent good candidates for vaccine development. Alterna-
tively, these proteins classes may have received greater
attention from the research community, in terms of
epitope discovery, because of their high level of expres-
sion or ease of isolation. Increased epitope identification
in proteins belonging to categories with low epitope den-
sity may allow discrimination between these two alterna-
tives, and may also lead to discovery of novel antibody/B
and T cell reactivities.
The epitope density of Mycobacterial proteins Figure 2
The epitope density of Mycobacterial proteins. Epitope Density Index (EDI) values for each protein function (a) and 
topology (b) category are shown. EDI 1 values (black) represent the number of epitopes in each category divided by the 
number of proteins with defined epitopes in the category. EDI 2 values (grey) represent the number of epitopes in each cate-
gory per 100 amino acid residues of proteins with defined epitopes in the category.Immunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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Mycobacterial strain and species distribution of described 
epitopes
The focus of the present analysis is Mtb, because of its sig-
nificance as a human pathogen. However, immune
epitope data from other all mycobacterium species for
which epitopic information is available were also
included. These data are important to appreciating the rel-
ative balance of knowledge between the various mycobac-
terium species and their relevance to vaccine and
diagnostic target selection. A total of 1644 epitopes have
been defined within 11 different mycobacterium species,
representing 363 antibody/B cell epitopes and 1281 T cell
epitopes. As previously stated, the total of unique myco-
bacterial epitopes is 1377, therefore some unique
epitopes are defined in more than one mycobacterium
species or strain, as well being recognized by both B and T
cell types [Additional file 1 (sheet1)]. As shown in Figure
3, Mtb epitopes represents 56% of the total, while M. lep-
rae (ML) and M. bovis (Mb) represent 21 and 20% respec-
tively. Only 11 epitopes have been defined in M. avium
(>1%), and 23 epitopes are defined in other known myco-
bacteria species. A further 9 epitopes have been identified
in undetermined mycobacterium species.
Evidence that the genetic variability between Mtb strains
confers significant phenotypic differences in virulence
and immunogenicity [32], underscore the need for strain-
specific epitope analyses. Of the 924 epitopes defined in
Mtb, 54% were reported with no defined strain informa-
tion (Figure 3). Of the 417 Mtb strain-specific epitopes,
88% correspond to H37Rv, while the remainder corre-
sponds to strains 103, Erdman, H37Ra and CDC1551
[Additional file 1 (sheet1)]. Of the other Mtb strains of
potential interest, such as the laboratory strain H37Ra,
only 5 epitopes are known. Additionally, no epitopes are
described in other Mtb strains commonly associated with
TB, such as the highly virulent Beijing strains, or multi-
drug resistant (MDR) and or extremely drug resistant
(XDR) strains. A similar picture emerges in the case of the
epitopes defined in M. leprae, with the majority of the
epitopes derived from unidentified strains reflecting the
challenges in M. leprae strain typing [33,34]. This general
lack of strain information for epitopes was found to be, in
The distribution of epitopes between Mycobacterial species and strains Figure 3
The distribution of epitopes between Mycobacterial species and strains. The number of epitopes for each Mycobac-
teria species considered is presented. The proportion of epitopes with strain information (dark grey), and without (light grey) 
is shown for each species.Immunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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large part, due to the characterization of epitope recogni-
tion following natural Mycobacterial infection in human
populations. Indeed, 64% of mycobacterium-specific
epitopes within the IEDB were defined in humans. In this
context, the identity of the specific strain to which each
subject was exposed is often not known and/or not iden-
tified diagnostically. Moreover, this omission is com-
pounded by the lack of published sequence information
for some of the identified strains considered herein. In the
absence of strain characterization information, it is sug-
gested that the geographic location of origin and the eth-
nicity of study subjects be included in future publications.
Conservancy and uniqueness of mycobacterial epitopes
Establishing the degree of sequence conservancy for a
given epitope among and between mycobacterium spe-
cies and strains may help differentially identify epitopes
applicable to diagnostics, versus vaccine design and eval-
uations. In the diagnostic setting, epitopes conserved
within a species, and not found in any other mycobacte-
rium are of interest [35-37]. For example, reactivity to cer-
tain epitopes may distinguish between individuals
infected with Mtb and those previously vaccinated with
Bacillus Calmette-Guerin (BCG).
A total of 989 mycobacteria epitope sequences can be
found in the protein coding ORF's of 3 Mtb strains
(described in the methods section), accounting for 72% of
all Mycobacterial epitopes [Additional file 1 (sheet 2)]. Of
those, 95% are also conserved among Mtb strains. Eleven
of the conserved epitope sequences that are also exclusive
to Mtb (they do not share >85% sequence identity with
any other species) and are also conserved among three
Mtb-specific strains [Additional file 1 (sheet 3)]. These
epitopes have been identified as potential diagnostic can-
didates [38,39]. No epitope sequence exclusive to any M.
bovis strains was reported. Of the 427 epitope sequences
found in M. leprae TN, 89 are exclusive to this strain. This
higher number of unique sequences reflects the greater
evolutionary distance between M. leprae and the other
mycobacterium species considered [40]. Finally, of the
216 epitope sequences that were reported in M. avium,
206 were conserved within the two identified M. avium
strains, though none are exclusive to these strains.
For the purpose of distinguishing between infection with
M. tuberculosis, infection or sensitization to nontubercu-
lous mycobacteria, or immune responses due to vaccina-
tion with BCG, it is essential to know which sequences are
not shared with another species, regardless of exclusivity.
We found from of a total of 940 epitope sequences con-
served between the three Mtb strains, 216 are not present
in BCG Pasteur 1173P2 (Table 1). These epitopes might
be of diagnostic use in distinguishing between TB infec-
tion and vaccination. As expected, a substantially greater
number of Mtb conserved epitope are not shared with M.
leprae  and  M. avium. All of the 955 immune epitope
sequences present in the virulent AF2122/97 strain of M.
bovis are also be found in Mtb, while only 18 of the 940
conserved Mtb epitopes were found to be absent from M.
bovis.
Of the 955 sequences present in M. bovis strain AF2122/
97, 202 epitopes are not found in M. bovis BCG Pasteur
1173P2, reflecting known deletions in the BCG genome
[41]. These deleted epitopes may be of interest in studying
the difference in immune response between the BCG vac-
cine and virulent M. bovis. The majority of the sequences
present in M. bovis are not found in either M. leprae or M.
avium. A similar pattern is observed in the case of BCG. Of
the 427 epitope sequences found in M. leprae, 242 are
absent in Mtb, M. bovis, and M. bovis BCG, while 271 are
not found in M. avium. These sequences may discriminate
infections with M. leprae and other mycobacterial species.
Finally, all of the 206 epitope sequences conserved in M.
avium, 21 are not present in Mtb, 23 in M. bovis and BCG,
and 53 in M. leprae.
Hosts range of defined epitopes
In addition to humans, a variety of different host species
have been utilized to define mycobacterial epitopes. These
other hosts include mice, cattle, rabbits, rats, macaques,
Table 1: The numbers of Mycobacteria B and T cell epitope sequences that are present in one species but absent in another
The number of epitope sequences present in:
Species M. tuberculosis M. bovis M. bovis BCG M. leprae M. avium
Epitope sequences not found in: 940 1 955 2 761 2 427 2 2061
M. tuberculosis - 0 8 242 21
M. bovis 18 - 8 242 23
M. bovis BCG 1 216 202 - 242 23
M. leprae 757 770 576 - 53
M. avium 748 763 570 271 -
1 The total number of epitope sequences that are conserved between the strains of a species.2 The total number of epitope sequences that are 
present with the single strain information of a speciesImmunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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chickens, and guinea pigs. As pathogens, mycobacteria are
well-established in both human and veterinary medicine.
These bacterial infections are of particular significance to
the cattle, swine, and fowl industries. M. bovis infection in
cattle continues to have a substantial financial impact.
There is no information available for epitopes recognized
in other naturally-infected hosts, such badgers for M. bovis
or nine-banded armadillos for M. leprae.
Accordingly, we have investigated the mycobacterial
immune epitope information for the relevant animal
models and host species. A total of 1548 host-epitope
interactions, defined as an epitope experimentally deter-
mined to be recognized within a particular host species,
are distributed between different host species and
immune cell types. Therefore epitopes within the dataset
of 1377 unique epitopes are recognized by more than one
host species or immune cell type. The distribution of all
mycobacterial epitopes amongst the different host species
is shown in Table 2. Not surprisingly, the vast majority of
epitopes (63.7%) are defined in human hosts. Murine
epitopes account for an additional 24.1%, of which,
approximately a third have been defined in HLA trans-
genic mice, and are therefore restricted by human MHC
molecules. The epitopes described in bovine species
account for another 7.3% of the total. The number of
epitopes identified in other animal models is surprisingly
small. For example, only 15 are identified in the rat, and
1 in the guinea pig. In neither case are B cell epitopes rep-
resented as they are in the other listed species. Surpris-
ingly, only 9 epitopes have been defined in non-human
primates, accounting for less than 1% of the total. Thus
identification of additional epitopes in non-murine ani-
mal models, specifically those of non-human primates
might be of future interest.
In the majority of cases, the number of B cell epitopes
identified in each host organism is considerably less than
those for T cells, with the exception of epitopes identified
in chickens and rabbits. In these species, T cell epitopes
have yet to be described. This observation is likely a reflec-
tion of the preferential use of these species for antibody
production and the study of humoral immunity to TB.
Epitope recognition in different disease states
Using the definitions established by the CDC (as
described methods section), a total of 1460 human dis-
ease state classifications are known for the 985 epitopes
reported for naturally infected human hosts. As expected,
the recognition of some epitopes was reported for more
than one disease state, which explains the discrepancy in
the above totals. We found that the greatest proportion of
human recognitions of immune epitopes (Table 3) are
within the Clinically Active TB category (29%), followed
by Vaccinated (18%), then Prior TB (11%). Lower num-
bers are recognized in Exposed but not Diseased [house-
hold contacts, PPD-/+, TST-/+] (9%) and TB test positive
[TST, PPD, etc.] (7%) groups. M. leprae infections account
for most of the Exposed to Other Mycobacterium category
(23%). Only a small number of epitopes could not be
classified under the current disease state scheme (31, not
shown); including epitopes recognized in unspecified/
unknown or other diseases where mycobacterial involve-
ment is undetermined.
The IEDB also captures negative immunological data,
when it is reported in the literature and found to meet our
inclusion criteria. This feature of the database permits a
more in depth analysis of immune epitopes differentially
associated with certain diseases states. For example, a
given investigator might be interested in searching the
database for epitopes recognized by individuals with Clin-
ically Active TB, but not by vaccine recipients or individu-
als Exposed to other Mycobacteria. When we queried the
database for this specified type of epitope, 74 different
epitopes were found. Similarly, we queried for epitopes
Table 2: Recognition of Mycobacteria epitopes from different host species
Host Species No. of B cell Epitope Recognitions No. of T cell Epitope Recognitions Total No. of Epitope Recognitions1
Chicken 2 0 2 (0.1%)
Human 220 813 985 (63.6%)
Rabbit 46 0 46 (3.0%)
Rat 0 15 15 (1.0%)
Mouse 107 290 373 (24.1%)
Macaque 8 1 9 (0.6%)
Bovine 12 101 113 (7.3%)
Guinea pig 0 1 1 (0.1%)
Undetermined 3 1 4 (0.3%)
Total 398 1222 1548
1 The total for Both T and B cell epitopes may differ from the sum of epitopes in each category as some epitopes are recognized by both cell types.Immunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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reported in individuals in the Exposed/resolved category,
but not by those with Clinically Active TB. In this case a
total of 27 different epitopes were found. In general how-
ever, we noted that for most epitopes, information is
sorely lacking regarding recognition in multiple disease
states, thus limiting the usefulness of the positive recogni-
tion data, especially in diagnostic and prognostic settings.
Overall, the analysis underlines the need for controlled
systematic studies to correlate immune recognition of par-
ticular epitopes and antigens with disease states and out-
comes.
Animal models and protective epitopes
A total 618 mycobacterial epitopes have been identified in
non-human hosts. These epitopes been further catego-
rized into TB or non-TB animal models [42]. 492 epitopes
have been identified in TB models, while 126 have been
identified in non-TB models. As mentioned above, in
many instances, these epitopes were recognized in HLA
transgenic mice that express human MHC molecules.
Analogous to the human disease outcome scenario, it is
useful to be able to identify which of the reported epitopes
confer protection in experimental models of the disease.
Additional file 1 (sheet 4) lists protective epitopes that
have been reported in the literature for animal models of
Mtb infection. It should be noted that in our classification
of protective epitopes, we utilize a rather stringent defini-
tion. Namely, we only consider protective epitopes that
are utilized as isolated molecular structures to immunize
and confer protection, and do not consider protective
epitopes merely associated with protection in contexts
were responses directed against multiple epitope specifici-
ties are present. Moreover we define protection from dis-
ease in these animals as a reduction of clinical signs or
reduction in bacterial load.
Utilizing these stringent criteria, only 10 T cell epitopes
are shown to be protective in mice and rats. Four of the
protective epitopes are derived from the antigen 85 pro-
tein, 2 from the 6 kDa early secretory antigenic target
(ESAT-6) and 2 from the 60 kDa chaperonin 2 protein.
Although a monoclonal antibody specific to a Mtb
polysaccharide conferring partial protection on mice has
been identified [43], no protective B cell epitopes have
been reported in the literature that fulfill the curation
requirements of the IEDB. These data indicate that a more
comprehensive analysis of the protective nature of TB
epitopes is needed.
MHC binding data of Mycobacterial T cell epitopes
The analysis of MHC binding data can be valuable as a
means of preliminary epitope identification, and to con-
firm restriction assignments. In all, MHC binding infor-
mation is known for 436 of the 1114 T cell epitopes, of
which 148 are bound by more than one MHC molecule.
As shown in table 4, the majority of data is related to MHC
class II (63%). Class I binding data comprise almost all of
the remaining 36%, with Non-classical MHC restricted
epitopes (recognized by CD1 and H-2-M3 molecules)
contributing approximately 1% of the total.
Table 4: The restriction of T cell epitopes by MHC molecules
Species MHC Class I MHC Class II MHC Class Ib/Non-classical
Antigen type No. of epitopes Antigen type No. of epitopes No. of epitopes
Human 118 500 4
HLA-A 48 HLA-DP 4 -
HLA-B 61 HLA-DQ 9 -
HLA-C 0 HLA-DR 449 -
Undetermined 9 Undetermined 38 -
Murine - 47 - 113 8
Rat - 5 - 2 0
R h e s u s -1-3 0
Chimpanzee - 0 - 2 0
Bovine - 0 - 4 0
Table 3: Summary of epitope recognition in different TB disease 
states
Disease State No. of Epitopes Recognized
Clinically Active TB 422 (29%)
Prior TB 163 (11%)
Exposed but not Diseased 124 (9%)
Vaccinated 267 (18%)
Exposed to other Mycobacterium 332 (23%)
Unexposed 47 (3%)
TB Test Positive 105 (7%)
Total 1460Immunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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There are 13 different HLA class I antigens that restrict a
total of 118 different epitopes [Additional file 1 (sheet 5)].
Epitopes defined for HLA-A and HLA-B antigens are
approximately equal, while no mycobacterial epitopes
were reported to be restricted by HLA-C antigens. Epitopes
bound by HLA-A2, B35, and B53 are the most numerous
(46, 28, and 10 restrictions, respectively). Furthermore,
65% of all HLA class I restrictions are determined at the
level of allele specificity, with the major alleles being
A*0201 and B*3501. There are 500 known epitopes
bound by 25 different HLA Class II molecules [Additional
file 1 (sheet 5)]. The vast majority of epitopes are bound
by DR antigens (90%), while DP and DQ antigens bound
less than 10 epitopes each. The greatest number of
epitopes are bound to DRB1*0101, *0301, *0401,
*1501, and DRB5*0101. Finally, MHC binding informa-
tion can also identify degenerate MHC ligands, of poten-
tial importance for vaccine and diagnostic applications
because of their broad population coverage. Here we find
38 mycobacterial MHC ligands that have promiscuous
binding properties have been identified [Additional file 1
(sheet 6)].
Next, we wanted to assess whether Mtb epitopes defined
in human hosts would allow for balanced coverage of the
different HLA class II and class I alleles, especially those
most frequently expressed in ethnicities inhabiting areas
in which TB is endemic. To this end, the 10 most frequent
HLA class I and class II alleles found in each region of high
TB incidence were compiled, based on the WHO report on
TB incidence [44], and from the dbMHC database [45] of
allele frequencies [Additional file 1 (sheet 7)].
Given the lack of breath in HLA allele specific Mtb epitope
information discussed above, it is perhaps not surprising
that few of these alleles are associated with epitopes of
known restriction. Of the HLA class I alleles frequent in
endemic areas, 7 are associated with described epitopes.
Similarly, of the 33 class II alleles are most frequent in
regions with a high incidence of TB, Mtb epitopes are
known to be restricted by only 7 of these alleles, which
represents just 51 epitopes. There are no epitopes identi-
fied for HLA-DP, and only 5 HLA-DQ alleles have been
shown to present Mtb epitopes to T cells. Thirty Mtb
epitopes are restricted by DRB1*0101, which represents
more than half of the allele specific data for HLA-DR. In
conclusion, coverage of alleles frequently expressed in
endemic areas is sparse, and could be improved by addi-
tional research.
HLA antigen associations with the outcome of human TB
infection have been reported [46-50]. We have identified
15 HLA class I and 23 class II antigens and alleles antigens
[Additional file 1 (sheet 8)], thought to be associated with
susceptibility to, or protection from TB, within the pub-
lished literature. Similarly to what is found in the case of
the alleles frequently found in endemic areas, little infor-
mation exists for the epitopes presented by alleles associ-
ated with disease resistance or susceptibility. Interesting
results have been obtained in this area in the case of other
pathogens such as HIV, for which epitopes restricted by
beneficial class I HLA alleles have significantly stronger
selective pressure exerted on them [51]. For plasmodium,
evidence that HLA class I and II polymorphisms are asso-
ciated with progression of malaria has also been proposed
[52]. In light of this information additional studies in TB
might be of interest.
Finally, in terms of non-human hosts, MHC binding data
is available for only 5 species: mouse, rat, macaques,
chimpanzee, and cattle (Table 3). Murine MHC restriction
accounts for roughly 90% of the data. Finally, with regard
to specific MHC molecules, only 5 murine MHC mole-
cules have 10 or more known epitopes: H-2-Db, H-2-
IAg7, H-2-IAb, H-2-IEg7, H-2-IAd antigens [Additional
file 1 (sheet 9)]. In conclusion, significant numbers of
MHC restricted epitope data is available for non-human
hosts, though the majority corresponds to murine MHC
class II molecules.
Definition of reference set of Mtb epitopes
The IEDB is designed to be as comprehensive and inclu-
sive as possible. No attempt is made to privilege particular
datasets based on the origin, experimental technique, or
perceived quality or value of the data. This design allows
the user to query the database and select particular dataset
matching desired characteristics. This approach is rigor-
ous and associated with the least loss of information.
However, it is also associated with an important potential
drawback, namely the requirement of a fair level of famil-
iarity by the user with the intricacies linked to a particular
diseases or experimental systems. For this reason, stand-
ardized epitope reference datasets could be of significant
use in the assessment of host-pathogen interactions, the
development and testing of diagnostic assays, and vaccine
evaluations.
To guard against subjectivity and arbitrary inclusion or
exclusion of data, we propose that the definition of refer-
ence datasets be governed by objective criteria agreed
upon by the relevant research community. This strategy
has the advantage to allow automatic updates by inclu-
sion of new epitopes that match the objective criteria. We
have initially generated epitope reference datasets accord-
ing to the following criteria: 1) Ex vivo detection (defined
not needing in vitro restimulation for T cell recognition,
and by definition, positive binding in all antibody assays)
and 2) Use of standardized assays (defined as epitopes
associated with a list of assays recognized by community
experts as "gold standards"; we tentatively included ICS,Immunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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ELISPOT, and proliferation for T cells responses; and
ELISA and Antigen Competition of Ab Binding for anti-
body responses). The number of epitopes that fulfill the
first two criteria (ex vivo and standardized assays) is 735,
which represents approximately 53% of the total defined
epitopes. (Table 5). These epitopes are describe 344 B cell
epitopes and 484 T cell epitopes, of which 93 are recog-
nized by both immune cell types.
Next, we reasoned that researchers might be interested in
different subsets of the epitopes defined by ex vivo detec-
tion and standardized assays. For example, epitopes with
known MHC restriction and/or defined molecular struc-
tures. If we apply these criteria, we obtain a reference set
of 322 unique epitopes of which 182 B cell epitopes and
186 T cell epitopes (46 epitopes are recognized by both
immune cell types) (Table 5, [Additional file 1 (sheet
10)]). It is also of potential interest to define which
epitopes have been reported in at least two different pub-
lications or IEDB submissions. This limitation defines a
reference set of 177 unique epitopes, of which 67 B cell
epitopes and 166 T cell epitopes (56 epitopes are recog-
nized by both immune cell types) (Table [Additional file
1 (sheet 11)]). Clinical researchers might also be inter-
ested in seeing how the epitopes defined by ex vivo analy-
sis and standardized assays are distributed between the TB
different disease states, as well as in the more specific sub-
category reference datasets. These results demonstrate that
multiple customized epitope datasets can be generated to
best suite the varied needs of the scientific community.
We have also placed a detailed summary of these data on
the IEDB website [53] with an accompanying forum dis-
cussion thread [54] to obtain research community feed-
back as to the value of these reference sets, and
suggestions on how to improve them.
Conclusion
A comprehensive analysis of immune epitopes derived
from mycobacteria was performed with the aim to pro-
vide information that can be used to evaluate different
vaccine and diagnostic concepts and design new basic or
clinical studies. In total, 1377 epitopes were reported for
mycobacteria. The distribution was dominated by M.
tuberculosis, M. leprae, and M. bovis, while a handful of
epitopes were defined within other determined and unde-
termined species. The vast majority of epitopes are pep-
tidic in nature, with few non-peptidic or post-
translationally modified epitopes identified for mycobac-
teria. This observation represents a significant gap in our
knowledge base, because it is well appreciated that non-
peptidic and post-translationally modified antigens are
important in Mtb infection and also are of potential diag-
nostic value.
Roughly three times as many T cell epitopes were identi-
fied compared to B cell epitopes. For T cell epitopes, the
number of CD4+ T cell epitopes is more than 6 times
greater than that for CD8+ T cells. The dominance of CD4+
T cell epitopes likely represents the focus of the research
community in identifying epitopes restricted by the MHC
class II pathway as mediators of TB immunity, which is
due to the established importance of CD4+ T cells in con-
trol of M. tuberculosis infection in humans, non-human
primates, and mice. A small number of non-classical T cell
epitopes were also identified. For B cell epitopes, no dis-
continuous epitope sequences were identified. As an
intracellular pathogen, the paradigm has been that anti-
bodies provide a limited role in Mtb immunity. This view
has been challenged, with evidence suggesting that B cells
modulate the host response and confer optimal contain-
ment of the microbe [55], while antibodies can provide
protection from infection [43,23]. The role of antibody
responses remains relevant to diagnostic applications.
This may suggest that more research might be warranted
with regard to antibody responses and B cell epitope dis-
covery.
Overall, epitopes are derived from all different protein
functional categories of Mycobacteria. However, the
majority of epitopes were from proteins directly associ-
ated with pathogenicity, those that might be exposed on
the surface of the organism, or those that interact with the
host. Most strikingly, all of the epitopes reported come
from a total of 270 antigens, while the top 30 most fre-
quently recognized protein antigens by B and T cells con-
tain approximately two thirds of the epitopes. This
Table 5: Number of epitopes that satisfy each of the defined criteria for epitope datasets
Criteria No. of Unique Epitopes* No. of B cell Epitopes No. of T cell Epitopes
All mycobacterial epitopes 1377 357 1114
Ex vivo1 and standardized assays2 735 344 484
Ex vivo and standardized assays + MHC restriction/defined epitope3 322 182 186
Ex vivo and standardized assays + generalizability4 177 67 166
* The number of unique epitopes does not equal the sum of B and T cell epitopes as some epitopes are recognized by both cell types.1 defined as 
not needing in vitro restimulation for T cell recognition, and positive binding in all antibody assays.2defined as epitopes assayed by ICS, ELISPOT, and 
proliferation for T cells responses, and ELISA and antigen competition of antibody binding for B cell responses. 3known MHC restriction and/or 
defined molecular structures.4epitopes have been reported in two different publications or IEDB submissions.Immunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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distribution may indicate that these proteins are highly
immunogenic or, alternatively, may have received dispro-
portional attention from the research community in terms
of epitope discovery. The components of the TB vaccine
candidate Mtb72F, which is based upon the fusion of Mtb
32 and 39 kDa protein antigens, are examples of impor-
tant antigens with little epitope knowledge. The IEDB
contains information on two T cell epitopes in the 32 kDa
Mtb protein, one of which has also been identified in
response to the vaccine candidate [56]. Thus, increased
epitope identification in proteins belonging to categories
with low epitope density may lead to novel discoveries in
Mtb.
For the purpose of identifying epitopes that can be used
for diagnostic, therapeutic, and vaccine development, we
determined the number of epitope sequences conserved
in Mycobacteria species, and the number that are exclu-
sive to a particular strain or species. In general, the lack of
sufficiently large numbers of genomic sequences from var-
ious strains and isolates hinders a comprehensive com-
parative study. Epitope sequences conserved within a
particular species may prove useful in developing diag-
nostic candidates for mycobacterial infection, while
epitopes exclusive to a mycobacterial species might be of
use in investigating host-pathogen interactions and the
development of diagnostic tools. For example, differenti-
ating between BCG vaccinated and Mtb infected individu-
als.
In terms of the host species in which mycobacterial
epitopes were identified, almost two thirds were human,
followed by mouse and cattle. Very few epitopes (<1%)
have been described in non-human primates. This infor-
mation represents an imbalance of knowledge, and a
greater identification of epitopes in non-murine animal
models; specifically those of non-human primates would
facilitate basic studies, and the quantitative evaluation of
new vaccine candidates and diagnostics.
In studying the association of known epitopes with regard
to different TB disease states in humans, we found that the
greatest number of epitopes is recognized in the Clinically
Active TB disease state. The identification of disease state-
specific epitopes may represent the first step in the devel-
opment of new diagnostic and therapeutic reagents for TB.
To this end, we have also identified disease state-specific
epitopes for animal models of TB, as well as those deter-
mined by Exposure to other Mycobacterium, and those
for Clinically Active TB. In conclusion the classification of
different epitope studies according to different disease
states highlights the need for controlled systematic studies
to correlate recognition of particular immune epitopes
and mycobacterial antigens with disease states and out-
comes.
In the interest of investigating the association of HLA
expression with Mtb, we have examined the MHC restric-
tion of the reported mycobacterium T cell epitopes. We
found that while a large amount of relevant data exists, it
appears imbalanced. Of the epitopes with known MHC
restriction, approximately 80% are class II, 20%, are class
I and less than 1% are non-classical HLA restricted. Most
data for class I is described by a small number of HLA anti-
gens and alleles, while almost all of the class II data relates
to HLA-DR. The coverage of Mtb epitopes in HLA antigens
and alleles that are either found more frequently in TB
endemic regions, or are considered to be associated with
TB disease in population studies, can both be described as
limited. Broader characterization of HLA class I and class
II antigens is required in order to understand the connec-
tion between HLA restricted epitope repertoires and TB
disease, since such information is lacking for most of the
known mycobacterial epitopes.
Finally, reference sets of epitope data that could be of sig-
nificant use to the research community for clinical and
basic studies, as well as the development and assessment
of diagnostic assays and vaccine evaluations. The uses of a
standardized assay and ex vivo detection were a prerequi-
site in determining the suitability of the epitopes consid-
ered. These epitopes have been made available on the
IEDB website. We expect these multiple reference epitope
datasets will be of great utility for the Mtb research com-
munity.
In summary, a comprehensive analysis of Mtb and other
Mycobacterial B and T cell epitopes has shown that a sig-
nificant amount of epitope data exists for researchers to
utilize. This study provides the general scientific commu-
nity with an objective evaluation of which information is
well represented within the current literature, where gaps
exist, and areas that might be addressed by future investi-
gations.
Methods
Primary source information
The functionality of Mycobacterial derived B and T cell
epitopes that are currently described in the published lit-
erature was first determined. As of September 1st 2007,
approximately 2000 references containing Mycobacteria-
specific keywords were identified by broad queries con-
ducted against the PubMed publication library. Of these,
296 contained epitope information meeting the criteria
established for inclusion into the IEDB, as described else-
where [57]. In addition, epitopes from 2 direct submis-
sions to the IEDB by NIAD-support research contracts
were also included (BAA-DAIT-04-39 [58]). It should be
noted that only molecular structures of less than 50 resi-
dues/5000 Daltons MW are currently captured in the data-Immunome Research 2007, 3:10 http://www.immunome-research.com/content/3/1/10
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base, and that predicted or modeled epitopes are also not
curated.
Definition of Mycobacterial epitope dataset
All Mycobacterial epitopes within the IEDB were identi-
fied by querying database entry fields. A dataset of 1377
unique Mycobacterial epitopes was identified. Informa-
tion for each unique epitope was utilized to further char-
acterize and separate the dataset as required each analysis
described.
To maximize the biological relevance of our analysis we
did not classify epitopes based on the presence MHC
binding data alone. Also, data in which isolated epitopes
were used to both immunize and detect responses were
also excluded as these 'cryptic' epitopes may not be repre-
sentative of the natural immune response. While innate
immune responses are also relevant in Mtb infection, it is
currently beyond the scope of the IEDB.
Assignment of CD4+ & CD8+ T cell epitopes
T cell epitopes were further categorized as associated with
MHC class I, MHC class II, or non-classical MHC class Ib.
The use of purified CD4+ or CD8+ T cells in the assay was
also used to classify epitopes as Class I or Class II, respec-
tively. In cases where MHC restriction was not reported an
assignment was made based upon the type of used. For
CD8+  T cells, assignments were based on chromium
release, or cytotoxicity assays. While CD4+ T cells were
inferred if the T cell assay measured cell proliferation,
DTH, production of lymphokines, such as IL5, IL4, IL10,
and TGFβ.
Assignment of Protein Function and Topology
Proteins for which Mycobacterial epitopes are known
were assigned a function and topology category. The 4
protein topology categories defined by the PSORT data-
base [59] and the 12 categories that describe gene func-
tion, as defined by the Pasteur Institute [14]. The protein
topology catergories are as follows: 1) Extracellular, 2)
Cell wall, 3) Cytoplasmic, and 4) Cytoplasmic Mem-
brane. Protein function categories are: 1) Virulence,
detoxification, adaptation, 2) Unknown function, 3)
Lipid metabolism, 4) Cell wall and cell processes, 5) PE/
PPE, 6) Information pathways, 7) Intermediary metabo-
lism and respiration, 8) Insertion sequences and phages,
9) conserved hypotheticals, 10) Conserved hypotheticals
with an orthologue in M. bovis, 11) Regulatory proteins,
and 12) Pseudogenes
Mycobacterial genomic information
The complete genome sequences from 3 Mtb strains: F11,
CDC1551, H37Rv [GenBank: CP000717.1, AE000516.2,
AL123456.2], M. bovis strains AF2122/97 [Gen-
Bank:BX248333.1] and BCG Pasteur 1173P2 [Gen-
Bank:AM408590.1],  M. leprae TN
[GenBank:AL450380.1], and 2 M. avium strains: 104, and
subsp. paratuberculosis K-10 [GenBank:CP000479.1,
AE016958.1] were utilized. The 2 M. bovis strains were
considered separately so that differences between the BCG
vaccine and pathogenic strains could be highlighted. For
the species represented by more than one strain, the
number of epitope sequences that are conserved was also
established. In addition, we determined the number of
epitopes exclusive to a given species (if no sequence with
≥ 80% identity is present in other species genomes).
Disease state assignment of epitopes
Following reported classifications for TB infection in
humans (Diagnostic Standards and Classification of
Tuberculosis in Adults and Children. 2000) [42] we dis-
tinguish Mycobactera epitopes according to: 1) Clinically
active TB, 2) Prior TB, 3) Exposed but not diseased 4) Vac-
cinated, 5) Exposed to other Mycobacterium, 6) Unex-
posed, and 7) TB test positive.
According to this classification, the Clinically Active TB
category includes individuals symptomatic for TB with
Mtb present in clinical samples. Both recent transmissions
(clustering of cases, close contacts) and remote transmis-
sions are included in this category. The category of Prior
TB covers individuals who have had a previous history of
TB but are now asymptomatic. Individuals that have
abnormal x-ray findings, show no clinical symptoms but
are TB test positive are also categorized as Prior TB cases.
Individuals in the Exposed but not diseased category had
close contacts with diseased individuals but never con-
tracted the disease. The Vaccinated category includes sub-
jects that received M. bovis BCG or an antigen derived from
BCG or Mtb. Individuals Exposed to Other Mycobacte-
rium such as M. avium or M. leprae, form a separate disease
category, as well as those who test positive for TB but for
which no other information is available (presumption of
the causative agent is not possible because of PPD cross-
reactivity). Unexposed individuals come from non-
endemic/low TB burden areas and have not had any con-
tact with TB patients; these individuals are generally TB
test negative. Lastly, Animal models of TB include studies
in mice, rats, rabbits, guinea pigs, and non-human pri-
mates utilizing Mtb, M. bovis,  M. bovis BCG and their
derivative antigens, while Non-TB Mycobacterial animal
models utilize non-tuberculosis Mycobacterium. Herein,
immunization, immunogen, and disease details were
used to assign the epitopes to the different categories
[Additional file 1 (sheet 12)]).
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